Home › MARIZEV (Omarigliptin), Mercks Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan
 

Keywords :   


MARIZEV (Omarigliptin), Mercks Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan

2015-09-28 13:30:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved MARIZEV (omarigliptin) 25 mg and 12.5 mg tablets, an oral, once-weekly DPP-4 inhibitor indicated for the treatment of adults with type 2 diabetes. Japan is the first country to have approved omarigliptin. Language: English Contact: Media Contacts:Pam Eisele, 267-305-3558orMichael Close, 310-617-1067orKristen Drake, 908-236-4223orInvestor Contacts:Justin Holko, 908-740-1879orTeri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: in type japan approved

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05M&S website and app hit by technical issue
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Producers to be paid grid premiums for AngusLink beef scores
More »